» Articles » PMID: 12676580

Heat Shock Protein 90 As a Molecular Target for Cancer Therapeutics

Overview
Journal Cancer Cell
Publisher Cell Press
Specialty Oncology
Date 2003 Apr 5
PMID 12676580
Citations 210
Authors
Affiliations
Soon will be listed here.
Citing Articles

Geldanamycin, a Naturally Occurring Inhibitor of Hsp90 and a Lead Compound for Medicinal Chemistry.

Kitson R, Kitsonova D, Siegel D, Ross D, Moody C J Med Chem. 2024; 67(20):17946-17963.

PMID: 39361055 PMC: 11513894. DOI: 10.1021/acs.jmedchem.4c01048.


The Landscape of Smart Biomaterial-Based Hydrogen Therapy.

Xu M, Wu G, You Q, Chen X Adv Sci (Weinh). 2024; 11(39):e2401310.

PMID: 39166484 PMC: 11497043. DOI: 10.1002/advs.202401310.


New Class of Hsp90 C-Terminal Domain Inhibitors with Anti-tumor Properties against Triple-Negative Breast Cancer.

Zajec Z, Dernovsek J, Cingl J, Ogris I, Gedgaudas M, Zubriene A J Med Chem. 2024; 67(15):12984-13018.

PMID: 39042910 PMC: 11320583. DOI: 10.1021/acs.jmedchem.4c00932.


HSPA4 upregulation induces immune evasion via ALKBH5/CD58 axis in gastric cancer.

Suo D, Gao X, Chen Q, Zeng T, Zhan J, Li G J Exp Clin Cancer Res. 2024; 43(1):106.

PMID: 38589927 PMC: 11000359. DOI: 10.1186/s13046-024-03029-4.


Potential Value of HSP90α in Prognosis of Triple-Negative Breast Cancer.

Wang H, Chen Y, Cao B, Pei J Med Sci Monit. 2024; 30:e943049.

PMID: 38553816 PMC: 10989195. DOI: 10.12659/MSM.943049.